CD4 and neoplasm: The percentage of CD4+CD25+ Tregs in the spleen was significantly higher in the B16-tmCRT/39-272 tumor-bearing mice than in the B16-EGFP controls (16.88% vs 20.9%) (Figure 4(a)), which contributed to enhanced the tumorigenesis of B16-tmCRT/39-272.